文献速递血液净化与透析

血液透析滤过随机对照试验与登记真实世界人群特征的系统综述

Characteristics of Populations Included in Randomized Controlled Trials of Hemodiafiltration and Registry Real-Life Populations: A Systematic Review.
PubMed 文献 · Clin J Am Soc Nephrol · 2025-09-12

系统综述比较血液透析滤过(HDF)与血液透析的随机对照试验(RCT)及肾脏登记数据库中真实世界人群的特征。共纳入11项RCT(N=5108)和8个登记数据库(N=1,147,167),发现RCT主要集中在欧洲,且仅年龄、性别、糖尿病、心血管疾病、血管通路类型和透析龄被一致报告;糖尿病比例在RCT为26%、登记为43%,动静脉瘘/移植物比例分别为90%和70%。结论认为现有证据患者特征覆盖广泛但不完整,需真实世界研究验证。

要点

  • HDF与血液透析RCT患者特征覆盖广泛但不完整,主要限于欧洲。
  • 仅年龄、性别、糖尿病、心血管疾病、血管通路类型和透析龄被一致报告。
  • 糖尿病比例RCT为26% vs 登记43%,动静脉瘘/移植物比例90% vs 70%。

核心结论

  • 现有HDF与血液透析RCT和登记数据库的患者特征覆盖广泛但不完整,数据主要限于欧洲且仅核心变量被报告。
  • RCT与登记人群在糖尿病比例和血管通路类型上存在差异,支持开展真实世界研究以探索现有证据的适用性。

研究设计与样本

  • 系统综述,检索1966年至2024年5月的HDF与血液透析RCT,并检索Fresenius市场分析登记数据库(2024年更新)中欧洲、亚太和美洲包含HDF人群的登记。
  • 共纳入11项RCT(N=5108)和8个登记(N=1,147,167)。

主要发现

  • RCT中无美国研究,仅澳大利亚(N=124)和巴西(N=195)各有一项小型RCT,大多数试验来自欧洲。
  • RCT和登记中一致报告的关键特征仅为年龄、性别、糖尿病、心血管疾病、血管通路类型和透析龄,这些特征在RCT中存在中高度异质性。
  • 糖尿病比例在RCT为26%、在登记为43%;动静脉瘘/移植物患病率在RCT为90%、在登记为70%。

临床怎么用

  • 肾内科医生应认识到HDF现有RCT证据主要来自欧洲人群,在非欧洲人群中的应用需谨慎。
  • 临床决策时应考虑真实世界登记中糖尿病比例更高、动静脉瘘/移植物比例更低的人群特征差异。

局限性

  • 数据主要限于欧洲,且仅核心人口学和临床变量被一致报告。
  • 除年龄、性别、糖尿病、心血管疾病、血管通路类型和透析龄外,其他患者和治疗相关特征在RCT和登记中报告不规则或未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Coverage of patient characteristics in existing trials of hemodiafiltration versus hemodialysis seems to be broad but incomplete. Randomized trials of hemodiafiltration versus hemodialysis have been primarily limited to Europe. Inconsistencies between trials and registries support further studies using real-world data to explore applicability of existing evidence. BACKGROUND: Selection criteria in randomized trials (randomized controlled trials [RCTs]) can lead to differences in key characteristics between trial participants and real-life populations. We evaluated reporting of population characteristics in existing RCTs of hemodiafiltration (HDF) and in real-life populations included in kidney registries to descriptively identify key differences. METHODS: We used systematic review methodology to identify existing RCTs of HDF versus hemodialysis (1966 to May 2024). We also searched the Fresenius Quantitative Market Analysis team registry database (2024 update) for existing registries from Europe, the Asia-Pacific region, and America including populations on HDF. Patient characteristics from RCTs and registries were extracted, summarized, and compared descriptively. RESULTS: Eleven RCTs (N=5108) and eight registries (N=1,147,167) were identified. There were no RCTs in the United States and only two small RCTs from Australia (N=124) and Brazil (N=195). Most trials were from Europe. Key characteristics consistently reported in both RCTs and registries were only age, sex, diabetes, cardiovascular disease, vascular access type, and dialysis vintage. There was moderate to high heterogeneity for these patient characteristics in RCTs, indicating enrollment of a broad array of people. The proportion of people with diabetes was 26% in RCTs and 43% in registries. The prevalence of arteriovenous fistulas/graft was 90% in RCTs and 70% in registries. CONCLUSIONS: There was a broad but incomplete array of patient characteristics in existing RCTs and real-world registries of HDF versus hemodialysis. Data were primarily limited to Europe and only a core set of demographic and clinical variables. Apart for age, sex, diabetes, cardiovascular disease, vascular access type, and dialysis vintage, other patient and treatment relevant characteristics were erratically or not at all reported in RCTs as well as in real-world registries. With potential differences in patient populations, we support the need for studies examining HDF in real-world settings, e.g., with target emulation trials.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Cromm K, Pham N, Yuen T, et al. Characteristics of Populations Included in Randomized Controlled Trials of Hemodiafiltration and Registry Real-Life Populations: A Systematic Review. Clin J Am Soc Nephrol. 2025. PMID: 40938665. doi:10.2215/CJN.0000000855

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。